Week in Review: RuiYi (formerly Anaphore) Signs Up Shanghai's Genor to Develop mAb in China
5/20/2013 9:24:09 AM
More...
|
RuiYi (formerly Anaphore) and Genor BioPharma Collaborate on Development in China of RYI-008, a Novel Therapeutic for Autoimmune Diseases and Cancer
5/16/2013 10:08:27 AM
More...
|
CMC Biologics and RuiYi (formerly Anaphore) Enter into an Agreement for Development of a Novel Anti-IL-6 Monoclonal Antibody
5/14/2013 9:28:56 AM
More...
|
Anaphore Announces Name Change to RuiYi (formerly Anaphore) and New Additions to Shanghai Management Team
10/4/2012 6:45:47 AM
More...
|
Anaphore, Inc. Announces Acquisition of RuiYi in Shanghai China for GPCR Biologics Drug Discovery Platform
3/22/2012 10:07:32 AM
More...
|
Anaphore, Inc. Appoints Paul A. Grayson President and CEO
6/20/2011 6:55:37 AM
More...
|
Anaphore, Inc. Appoints Michael F. Haller, Ph.D., Senior Vice President of Strategic Partnerships and H Casey Logan Senior Vice President of Business Development
5/18/2011 9:12:28 AM
More...
|
Anaphore, Inc. to Present Company Overview with Focus on Atrimer Technology Platform at 13th Annual C21 BioVentures Conference
5/17/2011 9:15:43 AM
More...
|
Anaphore, Inc. Snags $110M Deal With Tanabe Research Laboratories U.S.A., Inc. to Make Drugs for Immune Disorders
12/13/2010 7:00:32 AM
More...
|
Anaphore, Inc. Names Former GlaxoSmithKline (GSK) Top Executive Dr. Russell G. Greig as Executive Chairman to Assist in Driving Anaphore's Pipeline of Next Generation Biological Therapies
6/10/2010 9:12:18 AM
More...
|
|